Member login

Forgot Password?
Return to login

European Commission

April 2013
What you need to know about Biosimilar Medicinal Products
- A Consensus Information Document

Please click here to view.

December 2015
IMS study: Impact of Biosimilar Competition

Please click here to read the full report.
Please click here to view the reading guide. 
Please click here to read the five observations by IMS.  

January 2017

European Commission Q&A for patients - Biosimilar medicines explained

Please click here to view

May 2017

QuintilesIMS -The Impact of Biosimilar Competition in Europe, Update

Please click here to view

European Medicines Agency

Scientific guidelines on biosimilar medicines

Please click here to view the whole range of documents.

Biosimilar medicines approved by the EMA

Please click here to view

Biosimilars in the EU - information guide to healthcare professionals

Please click here to view

IMS data

March 2016
Delivering on the Potential of Biosimilar Medicines

The Role of Functioning Competitive Markets, March 2016
Please click here to view
 

Medicines for Europe

Factors supporting a sustainable European biosimilars medicines market
- GfK report

Please click here to view.

FAMHP position on biosimilar medicines

Please click here to view the Belgian medicines agency position

The Nor-Switch study: More real world evidence of physician led switching to biosimilar medicines

Please click here for further details

European Commission Question & Answer Document for Patients Builds Trust and Understanding on Biosimilar Medicines across Europe

Please click here for further details

European Commission Initiative improves information for patients on biosimilar medicines

Please click here for futher details

Medicines Optimisation

January 2017

The Medicines Optimisation Hospital Trust Dashboard is hosted on NHS England’s website, please click here to view. 

MHRA

Drug safety update – biosimilar product

Please click here to view.

NHS England

April 2017
Cancer Vanguard

Please click here to view.

September 2015
What is a biosimilar medicine?

Please click here to view.

NICE

May 2010
Human growth hormone (somatropin) for the treatment of growth failure in children

Please click here to view.

November 2014
Erythropoiesis stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy

Please click here to view.

January 2015
NICE position paper on biosimilar medicines

Please click here to view.

February 2015
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Please click here to view.

July 2015
Introducing biosimilar versions of infliximab: Inflectra and Remsima

Please click here to view.

January 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

Please click here to view.

February 2016
Medicines optimisation: Key therapeutic topics

Please click here to view.

Professional Groups

BSG guidance on the use of biosimilar Infliximab CT-P13 in IBD, February 2016

Please click here to view.

RCP - UK IBD audit highlights potential huge cost savings of using new biosimilar medicines, September 2016 

Please click here to view

BOPA Guidelines - Implementation of Biosimilar MABs in Oncology, Role of Pharmacy, February 2017

Please click here to view